VivaCell Biotechnology GmbH

VivaCell Biotechnology GmbH is a research service provider specializing in in vitro and in vivo studies applicable in pharmaceuticals, nutraceuticals, and health products, focusing on tailored models for diverse client needs. VivaCell Biotechnology GmbH, founded in 2003 in Emmendingen, Germany, is engaged in providing research services. The company has not undergone any noted pivots or changes in operations. The founder's history is not specified, and there are no references to subsidiaries or parent companies.

Additionally, VivaCell has completed one deal as of April 9, 2025. VivaCell Biotechnology GmbH specializes in providing high-quality in vitro and in vivo research services across various sectors, including pharmaceuticals, nutraceuticals for both humans and animals, natural products, cosmetics, and oral care products. Their offerings include tailored models and protocols designed to meet the specific needs and indications of their clients, ensuring that the research is relevant and effective. The company has developed a range of research capabilities, particularly in areas such as cannabis and cannabinoid research, immuno­modulation, probiotic research, and metabolic diseases.

VivaCell serves a diverse client base that includes pharmaceutical companies, research institutions, and health product manufacturers, primarily in European and international markets. By focusing on customized solutions, VivaCell aims to address specific health-related challenges through innovative scientific approaches. VivaCell Biotechnology operates on a business model that includes direct partnerships and collaborations with clients in the pharmaceutical and nutraceutical industries. The company's revenue streams are generated from providing bespoke research services, which encompass project-based contracts and ongoing partnerships with clients for development and testing.

The company engages in transactions that may involve subscription models for long-term research agreements, or fee-for-service arrangements for individual projects. While specific pricing plans are not disclosed, it is anticipated that costs would vary based on the complexity and scope of the services offered, particularly for flagship projects such as their cannabis and cannabinoid research initiatives. This structured approach facilitates a steady revenue flow while fostering long-term client relationships in the research sector. In April 2025, VivaCell Biotechnology GmbH was acquired by 1Q Health GmbH, a portfolio company of Nord Holding.

The acquisition is intended to strengthen 1Q Health's market position. Future plans likely focus on integrating VivaCell's capabilities into 1Q Health's portfolio, potentially expanding product offerings and market reach.